---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/41521079.md"
description: "$Intellia Therap(NTLA.US) surged over 13%, driven by strong Phase 3 data for hereditary angioedema, which is expected to facilitate a rolling BLA submission. The potential U.S. launch is targeting the first half of 2027. Q1 revenue of $15 million also exceeded expectations, with net losses narrowing year-over-year. Cathie Wood's ARK bought 214,000 shares in a single day.What the gene editing sector currently lacks is the "delivery of clinical milestones." This time, the combination of strong Phase 3 data, regulatory progress, and institutional buying provides fundamental support for the sharp rise. The next focus will be on the review timeline for the BLA."
datetime: "2026-06-05T10:59:10.000Z"
locales:
  - [en](https://longbridge.com/en/topics/41521079.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/41521079.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/41521079.md)
author: "[人间半盏茶](https://longbridge.com/en/profiles/26892850.md)"
---

# $Intellia Therap(NTLA.US) surged over 13%, driven …


### Related Stocks

- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)